Monjuvi for DLBCL: How This Targeted Therapy Fits Into Modern Cancer Care

Monjuvi offers an antibody-based option for adults with relapsed or refractory diffuse large B-cell lymphoma in combination with lenalidomide, giving some patients a non-transplant treatment path in the United States.

Monjuvi is a prescription antibody therapy used with lenalidomide for certain adults with diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant, providing a targeted option in the United States for this aggressive blood cancer FDA, 07/31/2020.

As of: 06/10/2026 | Reading time: approx. 12 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Monjuvi (tafasitamab-cxix)
• Category: Targeted oncology therapy for DLBCL
• Brand/Manufacturer: Monjuvi by Incyte and MorphoSys
• Primary Use Cases: Adult patients with relapsed or refractory DLBCL ineligible for autologous stem cell transplant
• Availability: Prescription-only through oncology centers and specialty pharmacies in the United States
• Core Markets: Oncology hospitals, cancer centers, hematology practices

What Monjuvi Is and How It Works

Monjuvi, the brand name for tafasitamab-cxix, is a humanized monoclonal antibody that targets the CD19 protein on B cells, including malignant B cells found in certain lymphomas FDA Prescribing Information, 08/2021.

Monjuvi is approved in combination with the immunomodulatory drug lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from low grade lymphoma, who are not candidates for autologous stem cell transplant FDA, 07/31/2020.

The therapy is designed to work through multiple mechanisms. By binding to CD19 on B cells, Monjuvi can flag malignant cells for destruction by immune effector mechanisms such as antibody-dependent cellular cytotoxicity and phagocytosis, while potentially also affecting signaling pathways inside the cancer cell Blood, 11/2020.

In clinical use, Monjuvi is administered as an intravenous infusion on a specific schedule in repeated 28-day cycles, initially with more frequent dosing that later tapers to every two weeks when combined with lenalidomide, followed by Monjuvi monotherapy once lenalidomide is discontinued according to the prescribing information FDA Prescribing Information, 08/2021.

Why Monjuvi Matters for US Consumers and Industry

Diffuse large B-cell lymphoma is one of the most common types of non-Hodgkin lymphoma in adults and can be aggressive, so patients whose disease returns or does not respond to initial therapy need additional options, especially when they are not candidates for transplant or more intensive treatments American Cancer Society, 04/2024.

For many US patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant, standard care historically included chemotherapy, palliative regimens, or clinical trials, and the introduction of a CD19-directed antibody such as Monjuvi combined with lenalidomide expands non-transplant treatment approaches in community and academic practice Journal of Clinical Oncology, 02/2022.

From an industry perspective, Monjuvi sits in a competitive and rapidly evolving segment of targeted therapies for B-cell malignancies, where clinicians and payers weigh mechanisms of action, administration settings, toxicity profiles, and the ability to deliver therapy in outpatient infusion centers across the United States OncLive, 06/2023.

Monjuvi in the US and Global Market

In the United States, Monjuvi is commercialized through a collaboration between Incyte and MorphoSys, with Incyte responsible for commercialization in the US and MorphoSys outside the US, reflecting a partnership-based approach to oncology drug launches across major regions Incyte, 07/31/2020.

US oncologists position Monjuvi plus lenalidomide alongside other options for relapsed or refractory DLBCL, including CAR T-cell therapies and other targeted agents, with selection influenced by patient age, comorbidities, prior treatments, and access to specialized centers or community-based infusion clinics Cancer Network, 09/2022.

Globally, access and reimbursement for Monjuvi depend on national regulatory approvals and health technology assessments, and while the US market remains a key driver due to the established oncology infrastructure and payer systems, expansion into additional regions supports broader availability for eligible lymphoma patients MorphoSys, 02/2020.

• CD19-directed antibody used with lenalidomide for adults with relapsed or refractory DLBCL not eligible for autologous stem cell transplant in the US.
• Delivered as intravenous infusions in 28-day cycles within oncology and hematology treatment settings.
• Represents a targeted, non-transplant option within a crowded landscape of therapies for aggressive B-cell lymphomas.

Frequently Asked Questions About Monjuvi

Who is Monjuvi for?
Monjuvi in combination with lenalidomide is indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant, under an accelerated approval pathway in the US FDA Prescribing Information, 08/2021.

How is Monjuvi given?
Monjuvi is administered as an intravenous infusion in 28-day cycles, initially on days 1, 4, 8, 15, and 22 of cycles 1 to 3, then on days 1 and 15 of subsequent cycles, in combination with lenalidomide, followed by Monjuvi monotherapy according to the US label FDA Prescribing Information, 08/2021.

Is Monjuvi available across the United States?
Monjuvi is available by prescription through US oncology practices, hospital-based infusion centers, and specialty pharmacies, with distribution managed under collaboration between Incyte in the US and MorphoSys internationally to support patient access.

MorphoSys AG is the biopharmaceutical company behind Monjuvi, collaborating with Incyte for US commercialization while focusing on antibody and oncology research and development.

The company is headquartered in Germany, and its shares are associated with the ISIN DE0006632003, anchoring Monjuvi within a broader portfolio of oncology-focused innovations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.